News | August 16, 2021
Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
EPS for the period at Rs. (7.57)
EPS for the period at Rs. (7.57)
The company expects revenue growth of 10-15 per cent in the US
The company has been consistently reducing debt
Total income grew in the quarter
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
